Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ruling.
The panel voted 9-2 that MDMA, when combined with talk therapy, is not effective in treating PTSD. The panel also voted 10-1 that the current benefits do not outweigh the potential risks of using the drug to treat mental issues.
Some members of the panel, like sociologist Elizabeth Joniak-Grant, pointed to allegations of misconduct in trials that could have skewed results as a reason for voting against the use of MDMA in PTSD patients, according to NPR.
Read Also: What's Going On With MindMed And Psychedelic Stocks?
美国食品与药品管理局（FDA）的顾问小组于周二拒绝了MDMA作为治疗创伤后应激障碍（PTSD）的药物，并指出缺乏证据表明将这种迷幻治疗方法引入患者的风险超过了其益处。由于此项裁决，大多数太空概念的股票在周三都受到了打击。
小组投票9-2认为，当MDMA与心理治疗结合使用时，并不能有效地对治疗PTSD起到作用。该小组还以10-1的比例投票认为，目前的益处并不能超过使用这种药物治疗精神问题的潜在风险。
根据NPR的报道，小组中的一些成员（如社会学家Elizabeth Joniak-Grant）认为，由于试验中的不当行为指控可能导致结果出现偏差，因此拒绝在PTSD患者中使用MDMA。
读者也应该看看：MindMed和迷幻股票发生了什么？
Market Movers: Many stocks in the psychedelic space traded lower Wednesday following the ruling. Cybin Inc (NYSEAMERICAN:CYBN), which develops drugs and treatments derived from psychedelic substances like psilocybin, was down by more than 10% Wednesday afternoon.
Mind Medicine (NASDAQ:MNMD), another biotech using psychedelic substances as a derivative for its treatments, traded lower by more than 8% Wednesday. ATAI Life Sciences (NASDAQ:ATAI) opened Wednesday's trading session down more than 14% from its closing price Tuesday, but was able to recover some of its losses throughout Wednesday's session, and last traded down around 6%.
The AdvisorShares Psychedelics ETF (NYSE:PSIL), a fund that tracks many publicly traded psych stocks, traded around 6% lower Wednesday afternoon.
许多太空概念股票在周三的裁决后交易低迷。Cybin公司（NYSEAMERICAN:CYBN）研发基于类似于蘑菇的迷幻物质的药物和治疗方法，周三下午下跌超过10%。
Mind Medicine（NASDAQ:MNMD）是另一家将迷幻物质用作其治疗方案的生物技术公司，周三下跌超过8%。ATAI Life Sciences（NASDAQ:ATAI）周三开盘股价比周二收盘价下跌了超过14%，但在周三的交易中恢复了一些损失，最后交易下跌约6%。
AdvisorShares Psychedelics ETF（NYSE:PSIL）是一只追踪许多公开交易的迷幻股票的基金，周三下午交易下跌约6%。
What's Next: While the FDA does not have to follow that advisory board's recommendation, the ruling was seen throughout the industry as a blow to the progress made in approving and regulating treatments that utilize psychedelics. Proponents of psych drugs argue that many show more effectiveness than mental health treatments currently available on the market.
尽管FDA不必遵循咨询委员会的建议，但是此项裁决在整个行业中被视为打击了批准和监管使用迷幻物质治疗的进展。精神药物的支持者认为，许多精神健康治疗方法目前市场上的效果都没有这些药物好。
Now Read: Nvidia Has 'Multi-Year Lead' On AMD, Intel: Bank Of America Analyst Expects Stock To Hit $1,500 Per Share
现在阅读：银行分析师预计，英伟达股票价格将达到1,500美元，英特尔和AMD相比具有多年的领先优势。
Photo: Shutterstock
Photo: shutterstock